Document And Entity Information
Document And Entity Information - shares | 6 Months Ended | |
Jun. 30, 2021 | Aug. 06, 2021 | |
Document Information [Line Items] | ||
Entity Central Index Key | 0000810509 | |
Entity Registrant Name | NAVIDEA BIOPHARMACEUTICALS, INC. | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Period Focus | Q2 | |
Document Fiscal Year Focus | 2021 | |
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Jun. 30, 2021 | |
Document Transition Report | false | |
Entity File Number | 001-35076 | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 31-1080091 | |
Entity Address, Address Line One | 4995 Bradenton Avenue, Suite 240 | |
Entity Address, City or Town | Dublin | |
Entity Address, State or Province | OH | |
Entity Address, Postal Zip Code | 43017-3552 | |
City Area Code | 614 | |
Local Phone Number | 793-7500 | |
Title of 12(b) Security | Common Stock | |
Trading Symbol | NAVB | |
Security Exchange Name | NYSEAMER | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 30,163,245 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) | Jun. 30, 2021 | Dec. 31, 2020 |
Current assets: | ||
Cash and cash equivalents | $ 7,114,103 | $ 2,670,495 |
Stock subscriptions and other receivables | 2,400,238 | 2,987,319 |
Inventory | 178,830 | 169,798 |
Prepaid expenses and other | 350,239 | 700,716 |
Total current assets | 10,043,410 | 6,528,328 |
Property and equipment | 848,085 | 845,379 |
Less accumulated depreciation and amortization | 731,098 | 713,217 |
Property and equipment, net | 116,987 | 132,162 |
Right-of-use lease assets | 458,280 | 458,280 |
Less accumulated amortization | 269,142 | 208,185 |
Right-of-use lease assets, net | 189,138 | 250,095 |
License agreements, patents and trademarks | 851,929 | 747,863 |
Less accumulated amortization | 147,346 | 127,622 |
License agreements, patents and trademarks, net | 704,583 | 620,241 |
Other assets | 227,192 | 227,192 |
Total assets | 11,281,310 | 7,758,018 |
Current liabilities: | ||
Accounts payable | 1,080,070 | 1,161,717 |
Accrued liabilities and other | 2,630,747 | 2,512,994 |
Notes payable | 0 | 745,443 |
Lease liabilities, current | 313,852 | 294,951 |
Total current liabilities | 4,024,669 | 4,715,105 |
Lease liabilities, net of current portion | 120,471 | 296,006 |
Deferred revenue | 700,000 | 700,000 |
Total liabilities | 4,845,140 | 5,711,111 |
Commitments and contingencies (See Note 11) | ||
Stockholders’ equity: | ||
Common stock; $.001 par value; 300,000,000 shares authorized; 30,145,718 and 27,149,691 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively | 221,142 | 218,146 |
Common stock subscribed; $.001 par value, 0 and 995,000 shares subscribed as of June 30, 2021 and December 31, 2020, respectively | 0 | 995 |
Common stock subscriptions receivable | 0 | (4,975,000) |
Additional paid-in capital | 370,181,268 | 375,428,014 |
Accumulated deficit | (364,697,612) | (359,056,683) |
Navidea stockholders' equity | 5,704,870 | 1,315,604 |
Noncontrolling interest | 731,300 | 731,303 |
Total stockholders’ equity | 6,436,170 | 2,046,907 |
Total liabilities and stockholders’ equity | 11,281,310 | 7,758,018 |
Non-Series Preferred Stock [Member] | ||
Stockholders’ equity: | ||
Preferred stock | 0 | 0 |
Series D Preferred Stock [Member] | ||
Current assets: | ||
Stock subscriptions and other receivables | 2,200,000 | |
Stockholders’ equity: | ||
Preferred stock. subscriptions | 22 | 132 |
Series D preferred stock subscriptions receivable | 0 | (10,300,000) |
Series E Preferred Stock [Member] | ||
Stockholders’ equity: | ||
Preferred stock | $ 50 | $ 0 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares | Jun. 30, 2021 | Dec. 31, 2020 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, shares authorized (in shares) | 300,000,000 | 300,000,000 |
Common stock, shares issued (in shares) | 30,145,718 | 27,149,691 |
Common stock, shares outstanding (in shares) | 30,145,718 | 27,149,691 |
Common stock subscription, shares authorized (in shares) | 0 | 995,000 |
Non-Series Preferred Stock [Member] | ||
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized (in shares) | 5,000,000 | 5,000,000 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Series D Preferred Stock [Member] | ||
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock subscriptions, subscribed (in shares) | 22,077 | 103,000 |
Series E Preferred Stock [Member] | ||
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized (in shares) | 50,000 | 50,000 |
Preferred stock, shares outstanding (in shares) | 50,000 | 0 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | 6 Months Ended | ||||||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |||||
Revenue: | ||||||||
Revenue from contract with customer | $ 13,000 | $ 9,000 | $ 36,000 | $ 24,000 | ||||
Grant and other revenue | 247,983 | 262,181 | 349,234 | 403,232 | ||||
Total revenue | 261,046 | 271,101 | 384,783 | 427,373 | ||||
Cost of revenue | 0 | 357 | 0 | 966 | ||||
Gross profit | 261,046 | 270,744 | 384,783 | 426,407 | ||||
Operating expenses: | ||||||||
Research and development | 1,498,056 | 1,281,779 | 2,720,810 | 2,281,048 | ||||
Selling, general and administrative | 1,432,610 | 1,329,591 | 3,663,355 | 3,157,345 | ||||
Total operating expenses | 2,930,666 | 2,611,370 | 6,384,165 | 5,438,393 | ||||
Loss from operations | [1] | (2,669,620) | (2,340,626) | (5,999,382) | (5,011,986) | |||
Other (expense) income: | ||||||||
Interest income (expense), net | 1,266 | 15,343 | (1,609) | 12,971 | ||||
Gain on extinguishment of debt | 0 | 0 | 366,000 | 0 | ||||
Other, net | (5,686) | (336) | (5,941) | (212) | ||||
Total other (expense) income, net | (4,420) | 15,007 | [2] | 358,450 | [2] | 12,759 | [2] | |
Net loss | (2,674,040) | (2,325,619) | (5,640,932) | (4,999,227) | ||||
Loss (income) attributable to noncontrolling interest | 1 | 1 | 3 | (1) | ||||
Deemed dividend on Series C Preferred Stock beneficial conversion feature | 0 | (77,778) | 0 | (77,778) | ||||
Net loss attributable to common stockholders | $ (2,674,039) | $ (2,403,396) | $ (5,640,929) | $ (5,077,006) | ||||
Loss attributable to common stockholders per common share (basic and diluted) (in dollars per share) | $ (0.09) | $ (0.11) | $ (0.20) | $ (0.24) | ||||
Weighted average shares outstanding (in shares) | 29,117,832 | 22,759,393 | 28,531,660 | 21,481,514 | ||||
Royalty [Member] | ||||||||
Revenue: | ||||||||
Revenue from contract with customer | $ 0 | $ 8,920 | $ 0 | $ 24,141 | ||||
License [Member] | ||||||||
Revenue: | ||||||||
Revenue from contract with customer | $ 13,063 | $ 0 | $ 35,549 | $ 0 | ||||
[1] | Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments, other than those expenses directly incurred by Navidea Europe, Navidea UK and MT. | |||||||
[2] | Amounts consist primarily of interest income and interest expense, which are not currently allocated to our individual reportable segments. |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) | Preferred Stock [Member] | Preferred Stock Subscription [Member] | Preferred Stock Subscriptions Receivable [Member] | Additional Paid-in Capital [Member]Private Placement [Member] | Additional Paid-in Capital [Member]Registered Direct Offering [Member] | Additional Paid-in Capital [Member] | Common Stock [Member]Private Placement [Member] | Common Stock [Member]Registered Direct Offering [Member] | Common Stock [Member] | Common Stock Subscription [Member]Private Placement [Member] | Common Stock Subscription [Member]Registered Direct Offering [Member] | Common Stock Subscription [Member] | Common Stock Subscriptions Receivable [Member]Private Placement [Member] | Common Stock Subscriptions Receivable [Member] | Retained Earnings [Member] | Noncontrolling Interest [Member] | Private Placement [Member] | Registered Direct Offering [Member] | Total |
Balance (in shares) at Dec. 31, 2019 | 0 | 19,234,960 | 902,162 | ||||||||||||||||
Balance at Dec. 31, 2019 | $ 0 | $ 345,847,676 | $ 210,232 | $ 902 | $ 0 | $ (347,671,102) | $ 731,303 | $ (880,989) | |||||||||||
Issued stock (in shares) | 902,162 | 1,000,001 | (902,162) | ||||||||||||||||
Issued stock | $ 699,000 | $ 902 | $ 1,000 | $ (902) | $ 700,000 | ||||||||||||||
Stock subscribed | $ 2,015,126 | 549,353 | $ 2,374 | $ 647 | $ (912,500) | $ 1,105,000 | 550,000 | ||||||||||||
Stock compensation expense | 39,246 | 39,246 | |||||||||||||||||
Net loss | (2,673,610) | 2 | (2,673,608) | ||||||||||||||||
Issued stock (in shares) | 902,162 | 1,000,001 | (902,162) | ||||||||||||||||
Issued stock | 699,000 | $ 902 | $ 1,000 | $ (902) | 700,000 | ||||||||||||||
Series D Preferred Stock subscribed (See Note 12) (in shares) | (2,373,529) | (647,058) | |||||||||||||||||
Series D Preferred Stock subscribed (See Note 12) | $ (2,015,126) | $ (549,353) | $ (2,374) | $ (647) | 912,500 | (1,105,000) | $ (550,000) | ||||||||||||
Balance (in shares) at Mar. 31, 2020 | 21,194,248 | 3,020,587 | |||||||||||||||||
Balance at Mar. 31, 2020 | 349,219,656 | $ 212,191 | $ 3,021 | (912,500) | (350,344,712) | 731,305 | (1,091,039) | ||||||||||||
Issued stock in payment of services (in shares) | 0 | 3,810 | |||||||||||||||||
Issued stock in payment of services | 4,801 | ||||||||||||||||||
Issued stock in payment of employee bonuses (in shares) | 53,315 | ||||||||||||||||||
Issued stock in payment of employee bonuses | 64,458 | $ 53 | 64,511 | ||||||||||||||||
Stock subscribed (in shares) | 2,373,529 | 647,058 | |||||||||||||||||
Balance (in shares) at Dec. 31, 2019 | 0 | 19,234,960 | 902,162 | ||||||||||||||||
Balance at Dec. 31, 2019 | $ 0 | 345,847,676 | $ 210,232 | $ 902 | 0 | (347,671,102) | 731,303 | $ (880,989) | |||||||||||
Issued stock to 401(k) Plan (in shares) | 32,651 | ||||||||||||||||||
Issued stock to 401(k) Plan | $ 40,000 | ||||||||||||||||||
Net loss | (4,999,227) | ||||||||||||||||||
Balance (in shares) at Jun. 30, 2020 | 0 | 24,547,961 | 461,729 | ||||||||||||||||
Balance at Jun. 30, 2020 | $ 0 | 350,178,082 | $ 215,545 | $ 462 | 0 | (352,748,108) | 731,304 | (1,622,715) | |||||||||||
Balance (in shares) at Dec. 31, 2019 | 0 | 19,234,960 | 902,162 | ||||||||||||||||
Balance at Dec. 31, 2019 | $ 0 | 345,847,676 | $ 210,232 | $ 902 | 0 | (347,671,102) | 731,303 | (880,989) | |||||||||||
Balance (in shares) at Dec. 31, 2020 | 132,250 | 27,149,691 | 995,000 | ||||||||||||||||
Balance at Dec. 31, 2020 | $ 132 | $ (10,300,000) | 375,428,014 | $ 218,146 | $ 995 | (4,975,000) | (359,056,683) | 731,303 | 2,046,907 | ||||||||||
Balance (in shares) at Mar. 31, 2020 | 21,194,248 | 3,020,587 | |||||||||||||||||
Balance at Mar. 31, 2020 | 349,219,656 | $ 212,191 | $ 3,021 | (912,500) | (350,344,712) | 731,305 | (1,091,039) | ||||||||||||
Issued restricted stock (in shares) | 10,000 | ||||||||||||||||||
Issued restricted stock | $ 10 | 10 | |||||||||||||||||
Issued stock to 401(k) Plan (in shares) | 32,651 | ||||||||||||||||||
Issued stock to 401(k) Plan | 39,801 | $ 33 | 39,834 | ||||||||||||||||
Issued stock (in shares) | 70,000 | 1,911,800 | 647,058 | (1,911,800) | (647,058) | ||||||||||||||
Issued stock | $ 70 | 699,930 | $ 1,912 | $ 647 | $ (1,912) | $ (647) | 520,030 | 520,030 | 700,000 | ||||||||||
Issued stock upon conversion of Preferred Stock (in shares) | (70,000) | 410,765 | |||||||||||||||||
Issued stock upon conversion of Series D Preferred Stock | $ 70 | 341 | $ (411) | ||||||||||||||||
Stock subscribed | 392,470 | 392,470 | |||||||||||||||||
Stock compensation expense | 34,588 | 34,588 | |||||||||||||||||
Net loss | (2,325,618) | (1) | (2,325,619) | ||||||||||||||||
Issued stock (in shares) | 70,000 | 1,911,800 | 647,058 | (1,911,800) | (647,058) | ||||||||||||||
Issued stock | $ 70 | 699,930 | $ 1,912 | $ 647 | $ (1,912) | $ (647) | 520,030 | 520,030 | 700,000 | ||||||||||
Series D Preferred Stock subscribed (See Note 12) | $ (392,470) | $ (392,470) | |||||||||||||||||
Balance (in shares) at Jun. 30, 2020 | 0 | 24,547,961 | 461,729 | ||||||||||||||||
Balance at Jun. 30, 2020 | $ 0 | 350,178,082 | $ 215,545 | $ 462 | 0 | (352,748,108) | 731,304 | (1,622,715) | |||||||||||
Issued stock in payment of employee bonuses (in shares) | 40,844 | ||||||||||||||||||
Issued stock in payment of employee bonuses | 106,970 | $ 41 | 107,011 | ||||||||||||||||
Issued restricted stock (in shares) | 10,000 | ||||||||||||||||||
Issued stock upon exercise of warrants (in shares) | 300,595 | ||||||||||||||||||
Issued stock upon exercise of warrants | (300) | $ 300 | |||||||||||||||||
Deemed dividend on Series C Preferred Stock | 77,778 | (77,778) | |||||||||||||||||
Issued stock upon conversion of Series C Preferred Stock | $ (70) | (341) | $ 411 | ||||||||||||||||
Balance (in shares) at Dec. 31, 2020 | 132,250 | 27,149,691 | 995,000 | ||||||||||||||||
Balance at Dec. 31, 2020 | $ 132 | $ (10,300,000) | 375,428,014 | $ 218,146 | $ 995 | $ (4,975,000) | (359,056,683) | 731,303 | $ 2,046,907 | ||||||||||
Issued stock to 401(k) Plan (in shares) | 30,018 | ||||||||||||||||||
Issued stock to 401(k) Plan | $ 77,000 | ||||||||||||||||||
Net loss | $ (5,640,932) | ||||||||||||||||||
Issued stock upon stock option exercise (in shares) | 2,000 | ||||||||||||||||||
Balance (in shares) at Jun. 30, 2021 | 50,000 | 22,077 | 30,145,718 | ||||||||||||||||
Balance at Jun. 30, 2021 | $ 50 | $ 22 | $ 370,181,268 | $ 221,142 | $ (364,697,612) | $ 731,300 | $ 6,436,170 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals) | 3 Months Ended |
Jun. 30, 2021USD ($) | |
Stock issuance cost | $ 50,671 |
Condensed Consolidated Statem_4
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||||||
Jan. 31, 2020 | Dec. 31, 2019 | Jun. 30, 2021 | Mar. 31, 2021 | Jun. 30, 2020 | Mar. 31, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | Dec. 31, 2020 | Dec. 31, 2019 | |
Cash flows from operating activities: | ||||||||||
Net loss | $ (2,674,040) | $ (2,966,892) | $ (2,325,619) | $ (2,673,608) | $ (5,640,932) | $ (4,999,227) | ||||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||||
Depreciation and amortization | 37,606 | 36,099 | ||||||||
Non-cash lease expense | 60,957 | 60,010 | ||||||||
Stock compensation expense | 263,478 | 73,834 | ||||||||
Gain on extinguishment of debt | 0 | 0 | (366,000) | 0 | ||||||
Value of stock issued to 401(k) plan for employer matching contributions | 76,846 | 39,834 | ||||||||
Value of stock issued in payment of employee bonuses | 0 | 171,522 | ||||||||
Value of stock issued in payment of services | 0 | 4,801 | ||||||||
Changes in operating assets and liabilities: | ||||||||||
Receivables | (130,218) | 756,622 | ||||||||
Inventory | (9,032) | 0 | ||||||||
Prepaid expenses and other assets | 350,477 | 866,070 | ||||||||
Accounts payable | (81,647) | 48,842 | ||||||||
Accrued and other liabilities | 71,825 | (71,232) | ||||||||
Lease liabilities | (156,634) | (139,800) | ||||||||
Deferred revenue | 45,928 | 166,805 | ||||||||
Net cash used in operating activities | (5,477,346) | (2,985,820) | ||||||||
Cash flows from investing activities: | ||||||||||
Payments for purchases of equipment | (2,707) | (1,947) | (2,707) | (8,406) | ||||||
Patent and trademark costs | (104,067) | (115,271) | ||||||||
Net cash used in investing activities | (106,774) | (123,677) | ||||||||
Cash flows from financing activities: | ||||||||||
Proceeds from issuance of preferred stock, including collection of stock subscriptions receivable | 10,475,000 | 700,000 | ||||||||
Proceeds from issuance of common stock | $ 812,000 | $ 1,900,000 | 2,133 | 3,025,040 | $ 1,100,000 | |||||
Proceeds from note payable | 0 | 366,000 | ||||||||
Principal payments on notes payable | (379,443) | (261,701) | ||||||||
Net cash provided by financing activities | 10,027,728 | 3,679,339 | ||||||||
Net increase in cash and cash equivalents | 4,443,608 | 569,842 | ||||||||
Cash and cash equivalents, beginning of period | $ 1,047,159 | $ 2,670,495 | $ 1,047,159 | 2,670,495 | 1,047,159 | $ 1,047,159 | ||||
Cash and cash equivalents, end of period | $ 1,047,159 | $ 7,114,103 | $ 1,617,001 | 7,114,103 | 1,617,001 | $ 2,670,495 | $ 1,047,159 | |||
Preferred Stock Issuance Costs [Member] | ||||||||||
Cash flows from financing activities: | ||||||||||
Payment of stock issuance costs | (69,962) | 0 | ||||||||
Common Stock Issuance Costs [Member] | ||||||||||
Cash flows from financing activities: | ||||||||||
Payment of stock issuance costs | $ 0 | $ (150,000) |
Note 1 - Summary of Significant
Note 1 - Summary of Significant Accounting Policies | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | 1. Summary of Significant Accounting Policies a. Basis of Presentation: June 30, 2021 three six June 30, 2021 2020 June 30, 2021 not December 31, 2020, 10 Our condensed consolidated financial statements include the accounts of Navidea and our wholly owned subsidiaries, Navidea Biopharmaceuticals Europe Limited (“Navidea Europe”) and Navidea Biopharmaceuticals Limited (“Navidea UK”), as well as those of our majority-owned subsidiary, Macrophage Therapeutics, Inc. (“MT”). All significant inter-company accounts were eliminated in consolidation. b. Financial Instruments and Fair Value: ( 1 Cash and cash equivalents, stock subscriptions and other receivables, and accounts payable: ( 2 Notes payable: June 30, 2021 December 31, 2020 June 30, 2021 December 31, 2020, 9. c. Revenue Recognition: We also earn revenues related to our licensing and distribution agreements. The consideration we are eligible to receive under our licensing and distribution agreements typically includes upfront payments, reimbursement for research and development costs, milestone payments, and royalties. Each licensing and distribution agreement is unique and requires separate assessment in accordance with current accounting standards. See Note 3. d. Leases: 2018. 12 not 10. e. Convertible Preferred Stock: 480, Distinguishing Liabilities from Equity 815, Derivatives and Hedging 470, Debt 268, Presentation in Financial Statements of Redeemable Preferred Stocks not not No. 2020 06, Accounting for Convertible Instruments and Contracts in an Entity s Own Equity January 1, 2021, not not 12. f. Recently Adopted Accounting Standards: December 2019, No. 2019 12, Income Taxes (Topic 740 2019 12 2019 12 740 2019 12 December 12, 2020, 2019 12 not In August 2020, No. 2020 06, Accounting for Convertible Instruments and Contracts in an Entity s Own Equity 2020 06 2020 06 2020 06 2020 06 December 15, 2021, December 15, 2023 2020 06 January 1, 2021 2020 06 not g. Recently Issued Accounting Standards: May 2021, No. 2021 04, Issuer s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options 2021 04 ASU2 021 04 ASU2021 04 2021 04 December 15, 2021, not 2021 04 |
Note 2 - Liquidity
Note 2 - Liquidity | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Substantial Doubt about Going Concern [Text Block] | 2. Liquidity As disclosed in the notes to the financial statements included in the Company’s Annual Report on Form 10 11. In addition, the Company is engaged in ongoing litigation with our former President and Chief Executive Officer, Dr. Michael Goldberg. See Note 11. The Company has also been engaged in ongoing litigation with Capital Royalty Partners II L.P. (“CRG”) and pursuing recovery of approximately $4.3 million and other damages. See Note 11. On August 30, 2020, 10 $5.0 second 2021, June 30, 2021. 12. On August 31, 2020, one nine 3 July 8, 2021 ( no June 30, 2021. 12 17. On March 2, 2021, 10 none 12. Navidea intends to use the net proceeds from these transactions to fund its research and development programs, including continued advancement of its two 2b 3 Tc99m The Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was enacted on March 27, 2020. 7 May 18, 2020, February 23, 2021, 9. We do not 19 19 NAV3 32 19 19 The Company has experienced recurring net losses and has used significant cash to fund its operations. The Company has considerable discretion over the extent of development project expenditures and has the ability to curtail the related cash flows as needed. The Company also has funds remaining under outstanding grant awards, and continues working to establish new sources of funding, including collaborations, potential equity investments, and additional grant funding that can augment the balance sheet. However, based on our current working capital and our projected cash burn, management believes that there is substantial doubt about the Company's ability to continue as a going concern for a period of one 10 No |
Note 3 - Revenue From Contracts
Note 3 - Revenue From Contracts With Customers | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Revenue from Contract with Customer [Text Block] | 3. Revenue from Contracts with Customers Navidea is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. We manage our business based on two Tc99m Tc99m one Tc99 not May 11, 2020, The Company also has an agreement in place to provide Meilleur Technologies, Inc., (“Meilleur”), a wholly-owned subsidiary of Cerveau Technologies, Inc. (“Cerveau”), worldwide rights to conduct research using NAV4694, NAV4694 Currently, the Company recognizes revenue from up-front license fees and pre-market milestones after the cash has been received from its customers and the performance obligations have been met. Payments for sales-based royalties and milestones are generally received after the related revenue has been recognized and invoiced. Normal payment terms generally range from 15 to 90 days following milestone achievement or royalty invoice, in accordance with each contract. Up-front and milestone payments received related to our license and distribution agreements in India and China are deferred until Tc99m not Tc99m not no not eight ten The transaction price of a contract is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to a customer. Transaction prices do not third not When estimating a contract’s transaction price, the Company considers all the information (historical, current, and forecasted) that is reasonably available to it and identifies possible consideration amounts. Most of the Company’s contracts with customers include both fixed and variable components of the transaction price. Under those contracts, some or all of the consideration for satisfied performance obligations is contingent on events over which the Company has no Tc99m The milestone payments have a binary outcome (that is, the Company will either receive all or none not Royalties are estimated based on the expected value method because they are based on a variable amount of sales representing a range of possible outcomes. However, when taking into account the constraint on variable consideration, the estimate of future royalties included in the transaction price is generally $0. This conclusion is based on the fact that Tc99m not no no The sublicense of NAV4694 No. 606, Revenue from Contracts with Customers 606” Up-front fees, milestones and royalties are generally non-refundable. Therefore, the Company does not During the three June 30, 2021 2020, six June 30, 2021 2020, three six June 30, 2021 2020, not The following table disaggregates the Company’s revenue from contracts with customers for the three six June 30, 2021 2020. Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Royalty revenue: Tc99m tilmanocept - Europe $ — $ 8,920 $ — $ 24,141 License revenue: Tc99m tilmanocept - Europe $ 13,063 $ — $ 35,549 $ — The following economic factors affect the nature, amount, timing and uncertainty of the Company’s revenue and cash flows as indicated: Geographical Location of Customers: may may Tc99m Status of Regulatory Approval: Tc99m Tc99m Tc99m not may NAV4694 not Through June 30, 2021, not The following table summarizes the changes in contract liabilities, the current portion of which is included in accrued liabilities and other in the condensed consolidated balance sheets, during the three six June 30, 2021 2020. Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Total deferred revenue, beginning of period $ 700,000 $ 700,000 $ 700,000 $ 700,000 Revenue deferred related to sublicense — 160,000 — 160,000 Revenue recognized from satisfaction of performance obligations — — — — Total deferred revenue, end of period $ 700,000 $ 860,000 $ 700,000 $ 860,000 The Company had license revenue receivable of approximately $98,000 and $59,000 outstanding as of June 30, 2021 December 31, 2020. In addition to revenue from contracts from customers, we also generate revenue from National Institutes of Health (“NIH”) grants to support various product development initiatives. The revenue recognition standard applies to revenue from contracts with customers. A customer is defined as a party that has contracted with an entity to obtain goods or services that are an output of the entity’s ongoing major or central operations in exchange for consideration. The Company’s ongoing major or central operations consist of the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The NIH and its various institutes are responsible for biomedical and public health research and provide major biomedical research funding to non-NIH research facilities and entities such as Navidea. While the Company will directly benefit from any knowledge gained from the project, there is also a public health benefit provided, which justifies the use of public funds in the form of the grants. Based on the nature of the Company’s operations and the terms of the grant awards, Navidea does not not three June 30, 2021 2020, six June 30, 2021 2020, On May 11, 2020 ( March 5, 2015 ( Tc99m Pursuant to the Termination Agreement, the parties agreed that neither owed the other any payments due under the License Agreement as of the Termination Date and that, among other things, SpePharm no six ninety third 2021. |
Note 4 - Stock-based Compensati
Note 4 - Stock-based Compensation | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Share-based Payment Arrangement [Text Block] | 4. Stock-Based Compensation For the three June 30, 2021 2020, six June 30, 2021 2020, not three six June 30, 2021 2020. A summary of the status of our stock options as of June 30, 2021, six Six Months Ended June 30, 2021 Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Outstanding, January 1, 2021 549,970 $ 8.81 8.0 $ 209,280 Granted 232,000 2.54 Exercised (2,000 ) 1.06 Cancelled/Forfeited (67,600 ) 4.01 Outstanding, June 30, 2021 712,370 $ 7.25 7.8 $ 143,695 Exercisable, June 30, 2021 186,638 $ 15.64 5.3 $ 52,874 The weighted average grant date fair value per stock option granted during the six June 30, 2021 six June 30, 2021 A summary of the status of our unvested restricted stock as of June 30, 2021, six Six Months Ended June 30, 2021 Number of Shares Weighted Average Grant-Date Fair Value Unvested, January 1, 2021 60,000 $ 2.90 Granted 15,000 2.17 Vested (15,000 ) 1.47 Unvested, June 30, 2021 60,000 $ 3.08 As of June 30, 2021, |
Note 5 - Loss Per Share
Note 5 - Loss Per Share | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Earnings Per Share [Text Block] | 5. Loss Per Share Basic loss per share is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common shares. Diluted loss per share reflects additional common shares that would have been outstanding if dilutive potential common shares had been issued. Potential common shares that may Diluted loss per common share for the six June 30, 2021 2020 The Company’s unvested restricted stock awards contain nonforfeitable rights to dividends or dividend equivalents, whether paid or unpaid (referred to as “participating securities”). Therefore, the unvested restricted stock awards are required to be included in the number of shares outstanding for both basic and diluted earnings per share calculations. However, due to our loss from continuing operations, 60,000 and 10,000 shares of unvested restricted stock for the six June 30, 2021 2020, |
Note 6 - Inventory
Note 6 - Inventory | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Inventory Disclosure [Text Block] | 6. Inventory The components of inventory as of June 30, 2021 December 31, 2020 June 30, 2021 December 31, \2020 Materials $ 77,750 $ 77,750 Finished goods 101,080 92,048 Total inventory $ 178,830 $ 169,798 During the three six June 30, 2021, |
Note 7 - Investment in Macropha
Note 7 - Investment in Macrophage Therapeutics, Inc. | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Investments in and Advances to Affiliates, Schedule of Investments [Text Block] | 7. Investment in Macrophage Therapeutics, Inc. In August 2018, one February 2019, may December 18, 2020 no 11 7. |
Note 8 - Accounts Payable, Accr
Note 8 - Accounts Payable, Accrued Liabilities and Other | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] | 8. Accounts Payable, Accrued Liabilities and Other Accounts payable as of June 30, 2021 December 31, 2020 June 30, 2021 December 31, 2020 second 2021, second June 30, 2021. |
Note 9 - Notes Payable
Note 9 - Notes Payable | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Debt Disclosure [Text Block] | 9. Notes Payable First Insurance Funding In November 2019, eight July 2020. Interest expense related to the FIF note payable totaled $2,000 and $5,000 during the three six June 30, 2020, IPFS Corporation In November 2020, seven June 2021. Interest expense related to the IPFS note payable totaled $1,000 and $4,000 during the three six June 30, 2021, June 30, 2021 December 31, 2020, Paycheck Protection Program The CARES Act was enacted on March 27, 2020. May 18, 2020, February 23, 2021, 2. Summary During the three June 30, 2021 2020, six June 30, 2021 2020, |
Note 10 - Leases
Note 10 - Leases | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Leases of Lessee Disclosure [Text Block] | 10. Leases We currently lease approximately 5,000 square feet of office space at 4995 June 2023. In addition, we currently lease approximately 25,000 square feet of office space at 5600 2021. October 2022 five not June 2017, October 2022. We also currently lease a vehicle at a monthly payment of approximately $300, expiring in September 2021, October 2024. Total operating lease expense was $44,000 and $50,000 for the three June 30, 2021 2020, six June 30, 2021 2020, The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company’s operating leases as of June 30, 2021. Maturity of Lease Liabilities Operating Lease Payments 2021 (remaining) $ 159,131 2022 291,111 2023 19,699 2024 1,355 Total undiscounted operating lease payments 471,296 Less imputed interest 36,973 Present value of operating lease liabilities $ 434,323 Balance Sheet Classification Current lease liabilities $ 313,852 Noncurrent lease liabilities 120,471 Total operating lease liabilities $ 434,323 Other Information Weighted-average remaining lease term for operating leases (years) 1.4 Weighted-average discount rate for operating leases 11.0 % Cash paid for amounts included in the present value of operating lease liabilities was $185,000 and $181,000 during the six June 30, 2021 2020, |
Note 11 - Commitments and Conti
Note 11 - Commitments and Contingencies | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | 11. Commitments and Contingencies We are subject to legal proceedings and claims that arise in the ordinary course of business. In accordance with ASC Topic 450, Contingencies not CRG Litigation As disclosed in the notes to the financial statements included in the Company’s Annual Report on Form 10 December 2017, March 3, 2017. March 2017, not June 2016 $66.0 $4.1 $4.1 $7.0 On April 9, 2018, 414, 414” $4.1 $59.0 The Company had also been engaged in ongoing litigation with CRG in the Court of Common Pleas of Franklin County, Ohio (the “Ohio Court”) related to Navidea’s claims that the CRG Lenders fraudulently induced Navidea to enter into a settlement agreement and breached the terms of the same through certain actions taken by the CRG Lenders in connection with the Global Settlement Agreement, pursuant to which Navidea agreed to pay up to $66.0 $66.0 $4.1 June 2016 $66.0 $66.0 $7.1 414 May 7, 2019, June 28, 2019. November 27, 2019, $66.0 April 9, 2018, 414 no December 5, 2019, 10th March 27, 2020, September 23, 2020. March 16, 2021, 10th November 27, 2019 not not April 30, 2021, July 20, 2021 August 5, 2021, CRG filed another lawsuit in the Texas Court in April 2018. not $7.1 414 August 28, 2020. December 18, 2020, February 1, 2021. July 1, 2021. not 2. Platinum Litigation In November 2017, March 3, 2017, October 31, 2018, no On November 30, 2018, January 22, 2019, September 5, 2019. November 25, 2019, not April 28, 2020 19 not June 4, 2020. September 2, 2020, September 23, 2020 June 28, 2021. 2. Goldberg Agreement and Litigation In August 2018, one 1,175,000 November 2018, On February 11, 2019, February 19, 2019, March 1, 2019, February 20, 2019, may December 18, 2020 no New York Litigation Involving Dr. Goldberg On February 20, 2019, April 26, 2019, June 13, 2019, third On December 26, 2019, third not The District Court also rejected Dr. Goldberg’s claim for wrongful termination as Chief Executive Officer of MT. In addition, the District Court found that Dr. Goldberg lacked standing to seek injunctive relief to force the removal of Dr. Claudine Bruck and Michael Rice from MT’s Board of Directors, to invalidate all actions taken by the MT Board on or after November 29, 2018 ( In addition, the District Court found Navidea’s breach of fiduciary duty claim against Dr. Goldberg for conduct occurring more than three On January 31, 2020, April 1, 2020, On January 27, 2020, July 9, 2020, 1 2 3 4 On August 24, 2020, not third On May 27, 2021, 1 2 3 not 4 not third 5 6 not Fact discovery in the New York Action has been completed and the Court has ordered that expert discovery be completed no November 30, 2021. Delaware Litigation Involving Dr. Goldberg On February 20, 2019, June 12, 2019, not May 23, 2019 A trial on MT’s claims against Goldberg for breach of fiduciary duty and conversion was held on December 1 December 3, 2020. three not not Derivative Action Involving Dr. Goldberg On July 26, 2019, November 20, 2019, April 3, 2020, not 2 7. NYSE American Continued Listing Standards Navidea must maintain compliance with NYSE American continued listing standards, including those relating to stockholders’ equity. Specifically, Sections 1003 $6.0 five June 30, 2021, Even if an issuer does not 1003 not 1 $50,000,000; $50,000,000 two three 2 1,100,000 $15,000,000 400 June 30, 2021, June 30, 2021 $50.0 may not may |
Note 12 - Equity
Note 12 - Equity | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Stockholders' Equity Note Disclosure [Text Block] | 12. Equity In December 2019, 2019. January 2020. December 31, 2019. In February 2020, two 2020. On August 30, 2020, 10 $5.0 December 31, 2020. second 2021, June 30, 2021. 2. On August 31, 2020, one $15.0 June 30, 2021. June 30, 2021. June 30, 2021, 10 December 31, 2020. $2.925 December 31, 2020. 2 17. On March 2, 2021, Under the Series E Preferred Stock Purchase Agreement, Mr. Scott was granted a right of first no 33.33% 13 1934, not third not no no may December 31, 2021 In connection with the private placement, the Company entered into a registration rights agreement (the “Registration Rights Agreement”), pursuant to which, among other things, the Company prepared and filed with the Securities and Exchange Commission (the “SEC”) a registration statement on Form S- 1 20% 13 144 not 1933, not may not Except with respect to transactions which may no one may not one 2. Navidea intends to use the net proceeds from these transactions to fund its research and development programs, including continued advancement of its Phase 2b 3 Tc99m 2. During the six June 30, 2021 2020, 401 During the six June 30, 2020, 2019 |
Note 13 - Stock Warrants
Note 13 - Stock Warrants | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Stock Warrants Disclosure [Text Block] | 13. Stock Warrants As of June 30, 2021, |
Note 14 - Income Taxes
Note 14 - Income Taxes | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | 14. Income Taxes Income taxes are accounted for under the asset and liability method in accordance with Accounting Standards Codification 740, Income Taxes Current accounting standards require a valuation allowance against DTAs if, based on the weight of available evidence, it is more likely than not may not June 30, 2021 December 31, 2020. In assessing the realizability of DTAs, management considers whether it is more likely than not not not not June 30, 2021. Current accounting standards include guidance on the accounting for uncertainty in income taxes recognized in the financial statements. Such standards also prescribe a recognition threshold and measurement model for the financial statement recognition of a tax position taken, or expected to be taken, and provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company believes that the ultimate deductibility of all tax positions is highly certain, although there is uncertainty about the timing of such deductibility. As a result, no liability for uncertain tax positions was recorded as of June 30, 2021 December 31, 2020 not twelve June 30, 2021, 2017 2020 As of June 30, 2021, 2021 2040. |
Note 15 - Segments
Note 15 - Segments | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Segment Reporting Disclosure [Text Block] | 15. Segments We report information about our operating segments using the “management approach” in accordance with current accounting standards. This information is based on the way management organizes and reports the segments within the enterprise for making operating decisions and assessing performance. Our reportable segments are identified based on differences in products, services and markets served. There were no inter-segment sales. We manage our business based on two Tc99m The information in the following tables is derived directly from each reportable segment’s financial reporting. Three Months Ended June 30, 2021 Diagnostics Therapeutics Corporate Total License revenue $ 13,063 $ — $ — $ 13,063 Grant and other revenue 247,983 — — 247,983 Total revenue 261,046 — — 261,046 Research and development expenses 1,358,123 139,933 — 1,498,056 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 873 1,411,879 1,412,752 Depreciation and amortization (2) 6,041 — 13,817 19,858 Loss from operations (3) (1,103,118 ) (140,806 ) (1,425,696 ) (2,669,620 ) Other expense (4) — — (4,420 ) (4,420 ) Net loss (1,103,118 ) (140,806 ) (1,430,116 ) (2,674,040 ) Total assets, net of depreciation and amortization: United States $ 269,464 $ — $ 10,811,515 $ 11,080,979 International 199,741 — 590 200,331 Capital expenditures — — 2,707 2,707 Three Months Ended June 30, 2020 Diagnostics Therapeutics Corporate Total Royalty revenue $ 8,920 $ — $ — $ 8,920 Grant and other revenue 215,458 46,723 — 262,181 Total revenue 224,378 46,723 — 271,101 Cost of revenue 357 — — 357 Research and development expenses 1,193,151 88,628 — 1,281,779 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 972 1,309,363 1,310,335 Depreciation and amortization (2) — — 19,256 19,256 Loss from operations (3) (969,130 ) (42,877 ) (1,328,619 ) (2,340,626 ) Other income (4) — — 15,007 15,007 Net loss (969,130 ) (42,877 ) (1,313,612 ) (2,325,619 ) Total assets, net of depreciation and amortization: United States $ 107,185 $ 36,483 $ 6,463,015 $ 6,606,683 Capital expenditures — — 1,947 1,947 Six Months Ended June 30, 2021 Diagnostics Therapeutics Corporate Total License revenue $ 35,549 $ — $ — $ 35,549 Grant and other revenue 349,234 — — 349,234 Total revenue 384,783 — — 384,783 Research and development expenses 2,452,513 268,297 — 2,720,810 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 2,879 3,622,870 3,625,749 Depreciation and amortization (2) 12,081 — 25,525 37,606 Loss from operations (3) (2,079,811 ) (271,176 ) (3,648,395 ) (5,999,382 ) Other income (4) — — 358,450 358,450 Net loss (2,079,811 ) (271,176 ) (3,289,945 ) (5,640,932 ) Total assets, net of depreciation and amortization: United States $ 269,464 $ — $ 10,811,515 $ 11,080,979 International 199,741 — 590 200,331 Capital expenditures — — 2,707 2,707 Six Months Ended June 30, 2020 Diagnostics Therapeutics Corporate Total Royalty revenue $ 24,141 $ — $ — $ 24,141 Grant and other revenue 274,374 128,858 — 403,232 Total revenue 298,515 128,858 — 427,373 Cost of revenue 966 — — 966 Research and development expenses 2,150,777 130,271 — 2,281,048 Selling, general and administrative expenses, excluding depreciation and amortization (1) — (550 ) 3,121,796 3,121,246 Depreciation and amortization (2) — — 36,099 36,099 Loss from operations (3) (1,853,228 ) (863 ) (3,157,895 ) (5,011,986 ) Other income (4) — — 12,759 12,759 Net loss (1,853,228 ) (863 ) (3,145,136 ) (4,999,227 ) Total assets, net of depreciation and amortization: United States $ 107,185 $ 36,483 $ 6,463,015 $ 6,606,683 Capital expenditures — — 8,406 8,406 ( 1 not ( 2 three June 30, 2021 2020, six June 30, 2021 2020, ( 3 not ( 4 not |
Note 16 - Supplemental Disclosu
Note 16 - Supplemental Disclosure for Statements of Cash Flows | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Cash Flow, Supplemental Disclosures [Text Block] | 16. Supplemental Disclosure for Statements of Cash Flows During the six June 30, 2021 2020, six June 30, 2021, 10 December 31, 2020 December 31, 2020. February 2020, six June 30, 2021 2020, 401 six June 30, 2020, 2019 six June 30, 2020, six June 30, 2020, |
Note 17 - Subsequent Events
Note 17 - Subsequent Events | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | 17. Subsequent Events The Company has evaluated events and transactions subsequent to June 30, 2021 10 On July 8, 2021, July 9, 2021 5 August 31, 2020 no The entire $2.2 million was received and the related 22,077 shares of Series D Preferred Stock were issued on July 8, 2021. June 30, 2021. 2 12. |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 6 Months Ended |
Jun. 30, 2021 | |
Accounting Policies [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | a. Basis of Presentation: June 30, 2021 three six June 30, 2021 2020 June 30, 2021 not December 31, 2020, 10 Our condensed consolidated financial statements include the accounts of Navidea and our wholly owned subsidiaries, Navidea Biopharmaceuticals Europe Limited (“Navidea Europe”) and Navidea Biopharmaceuticals Limited (“Navidea UK”), as well as those of our majority-owned subsidiary, Macrophage Therapeutics, Inc. (“MT”). All significant inter-company accounts were eliminated in consolidation. |
Fair Value of Financial Instruments, Policy [Policy Text Block] | b. Financial Instruments and Fair Value: ( 1 Cash and cash equivalents, stock subscriptions and other receivables, and accounts payable: ( 2 Notes payable: June 30, 2021 December 31, 2020 June 30, 2021 December 31, 2020, 9. |
Revenue [Policy Text Block] | c. Revenue Recognition: We also earn revenues related to our licensing and distribution agreements. The consideration we are eligible to receive under our licensing and distribution agreements typically includes upfront payments, reimbursement for research and development costs, milestone payments, and royalties. Each licensing and distribution agreement is unique and requires separate assessment in accordance with current accounting standards. See Note 3. |
Lessee, Leases [Policy Text Block] | d. Leases: 2018. 12 not 10. |
Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block] | e. Convertible Preferred Stock: 480, Distinguishing Liabilities from Equity 815, Derivatives and Hedging 470, Debt 268, Presentation in Financial Statements of Redeemable Preferred Stocks not not No. 2020 06, Accounting for Convertible Instruments and Contracts in an Entity s Own Equity January 1, 2021, not not 12. |
New Accounting Pronouncements, Policy [Policy Text Block] | f. Recently Adopted Accounting Standards: December 2019, No. 2019 12, Income Taxes (Topic 740 2019 12 2019 12 740 2019 12 December 12, 2020, 2019 12 not In August 2020, No. 2020 06, Accounting for Convertible Instruments and Contracts in an Entity s Own Equity 2020 06 2020 06 2020 06 2020 06 December 15, 2021, December 15, 2023 2020 06 January 1, 2021 2020 06 not g. Recently Issued Accounting Standards: May 2021, No. 2021 04, Issuer s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options 2021 04 ASU2 021 04 ASU2021 04 2021 04 December 15, 2021, not 2021 04 |
Note 3 - Revenue From Contrac_2
Note 3 - Revenue From Contracts With Customers (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Notes Tables | |
Disaggregation of Revenue [Table Text Block] | Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Royalty revenue: Tc99m tilmanocept - Europe $ — $ 8,920 $ — $ 24,141 License revenue: Tc99m tilmanocept - Europe $ 13,063 $ — $ 35,549 $ — |
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] | Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Total deferred revenue, beginning of period $ 700,000 $ 700,000 $ 700,000 $ 700,000 Revenue deferred related to sublicense — 160,000 — 160,000 Revenue recognized from satisfaction of performance obligations — — — — Total deferred revenue, end of period $ 700,000 $ 860,000 $ 700,000 $ 860,000 |
Note 4 - Stock-based Compensa_2
Note 4 - Stock-based Compensation (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Notes Tables | |
Share-based Payment Arrangement, Option, Activity [Table Text Block] | Six Months Ended June 30, 2021 Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Outstanding, January 1, 2021 549,970 $ 8.81 8.0 $ 209,280 Granted 232,000 2.54 Exercised (2,000 ) 1.06 Cancelled/Forfeited (67,600 ) 4.01 Outstanding, June 30, 2021 712,370 $ 7.25 7.8 $ 143,695 Exercisable, June 30, 2021 186,638 $ 15.64 5.3 $ 52,874 |
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] | Six Months Ended June 30, 2021 Number of Shares Weighted Average Grant-Date Fair Value Unvested, January 1, 2021 60,000 $ 2.90 Granted 15,000 2.17 Vested (15,000 ) 1.47 Unvested, June 30, 2021 60,000 $ 3.08 |
Note 6 - Inventory (Tables)
Note 6 - Inventory (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Notes Tables | |
Schedule of Inventory, Current [Table Text Block] | June 30, 2021 December 31, \2020 Materials $ 77,750 $ 77,750 Finished goods 101,080 92,048 Total inventory $ 178,830 $ 169,798 |
Note 10 - Leases (Tables)
Note 10 - Leases (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Notes Tables | |
Lessee, Operating Lease, Liability, Maturity [Table Text Block] | Maturity of Lease Liabilities Operating Lease Payments 2021 (remaining) $ 159,131 2022 291,111 2023 19,699 2024 1,355 Total undiscounted operating lease payments 471,296 Less imputed interest 36,973 Present value of operating lease liabilities $ 434,323 |
Lessee, Operating Lease, Assets and Liabilities [Table Text Block] | Balance Sheet Classification Current lease liabilities $ 313,852 Noncurrent lease liabilities 120,471 Total operating lease liabilities $ 434,323 |
Lease, Cost [Table Text Block] | Other Information Weighted-average remaining lease term for operating leases (years) 1.4 Weighted-average discount rate for operating leases 11.0 % |
Note 15 - Segments (Tables)
Note 15 - Segments (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Notes Tables | |
Schedule of Segment Reporting Information, by Segment [Table Text Block] | Three Months Ended June 30, 2021 Diagnostics Therapeutics Corporate Total License revenue $ 13,063 $ — $ — $ 13,063 Grant and other revenue 247,983 — — 247,983 Total revenue 261,046 — — 261,046 Research and development expenses 1,358,123 139,933 — 1,498,056 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 873 1,411,879 1,412,752 Depreciation and amortization (2) 6,041 — 13,817 19,858 Loss from operations (3) (1,103,118 ) (140,806 ) (1,425,696 ) (2,669,620 ) Other expense (4) — — (4,420 ) (4,420 ) Net loss (1,103,118 ) (140,806 ) (1,430,116 ) (2,674,040 ) Total assets, net of depreciation and amortization: United States $ 269,464 $ — $ 10,811,515 $ 11,080,979 International 199,741 — 590 200,331 Capital expenditures — — 2,707 2,707 Three Months Ended June 30, 2020 Diagnostics Therapeutics Corporate Total Royalty revenue $ 8,920 $ — $ — $ 8,920 Grant and other revenue 215,458 46,723 — 262,181 Total revenue 224,378 46,723 — 271,101 Cost of revenue 357 — — 357 Research and development expenses 1,193,151 88,628 — 1,281,779 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 972 1,309,363 1,310,335 Depreciation and amortization (2) — — 19,256 19,256 Loss from operations (3) (969,130 ) (42,877 ) (1,328,619 ) (2,340,626 ) Other income (4) — — 15,007 15,007 Net loss (969,130 ) (42,877 ) (1,313,612 ) (2,325,619 ) Total assets, net of depreciation and amortization: United States $ 107,185 $ 36,483 $ 6,463,015 $ 6,606,683 Capital expenditures — — 1,947 1,947 Six Months Ended June 30, 2021 Diagnostics Therapeutics Corporate Total License revenue $ 35,549 $ — $ — $ 35,549 Grant and other revenue 349,234 — — 349,234 Total revenue 384,783 — — 384,783 Research and development expenses 2,452,513 268,297 — 2,720,810 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 2,879 3,622,870 3,625,749 Depreciation and amortization (2) 12,081 — 25,525 37,606 Loss from operations (3) (2,079,811 ) (271,176 ) (3,648,395 ) (5,999,382 ) Other income (4) — — 358,450 358,450 Net loss (2,079,811 ) (271,176 ) (3,289,945 ) (5,640,932 ) Total assets, net of depreciation and amortization: United States $ 269,464 $ — $ 10,811,515 $ 11,080,979 International 199,741 — 590 200,331 Capital expenditures — — 2,707 2,707 Six Months Ended June 30, 2020 Diagnostics Therapeutics Corporate Total Royalty revenue $ 24,141 $ — $ — $ 24,141 Grant and other revenue 274,374 128,858 — 403,232 Total revenue 298,515 128,858 — 427,373 Cost of revenue 966 — — 966 Research and development expenses 2,150,777 130,271 — 2,281,048 Selling, general and administrative expenses, excluding depreciation and amortization (1) — (550 ) 3,121,796 3,121,246 Depreciation and amortization (2) — — 36,099 36,099 Loss from operations (3) (1,853,228 ) (863 ) (3,157,895 ) (5,011,986 ) Other income (4) — — 12,759 12,759 Net loss (1,853,228 ) (863 ) (3,145,136 ) (4,999,227 ) Total assets, net of depreciation and amortization: United States $ 107,185 $ 36,483 $ 6,463,015 $ 6,606,683 Capital expenditures — — 8,406 8,406 |
Note 1 - Summary of Significa_2
Note 1 - Summary of Significant Accounting Policies (Details Textual) - USD ($) | Jun. 30, 2021 | Dec. 31, 2020 |
Notes Payable, Fair Value Disclosure | $ 0 | $ 745,000 |
Note 2 - Liquidity (Details Tex
Note 2 - Liquidity (Details Textual) - USD ($) | Aug. 12, 2021 | Jul. 08, 2021 | Mar. 02, 2021 | Feb. 23, 2021 | Aug. 31, 2020 | May 18, 2020 | Aug. 12, 2021 | Jan. 31, 2020 | Dec. 31, 2019 | Nov. 30, 2017 | Jun. 30, 2021 | Mar. 31, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Dec. 31, 2019 | Dec. 31, 2020 | Aug. 30, 2020 |
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ 0.001 | $ 0.001 | $ 0.001 | $ 0.001 | |||||||||||||||
Proceeds from Issuance of Common Stock | $ 812,000 | $ 1,900,000 | $ 2,133 | $ 3,025,040 | $ 1,100,000 | ||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 2,100,000 | ||||||||||||||||||
Stock Issued During Period, Value, New Issues | $ 1,800,000 | $ 700,000 | |||||||||||||||||
Stock Subscriptions and Other Receivables | 2,400,238 | 2,400,238 | $ 2,400,238 | $ 2,987,319 | |||||||||||||||
Proceeds from Notes Payable, Total | 0 | 366,000 | |||||||||||||||||
Gain (Loss) on Extinguishment of Debt, Total | 0 | 0 | 366,000 | $ 0 | |||||||||||||||
Paycheck Protection Program CARES Act [Member] | |||||||||||||||||||
Proceeds from Notes Payable, Total | $ 366,000 | ||||||||||||||||||
Gain (Loss) on Extinguishment of Debt, Total | $ 366,000 | ||||||||||||||||||
Series D Preferred Stock [Member] | |||||||||||||||||||
Stock Issued During Period, Value, New Issues | $ 250,001 | ||||||||||||||||||
Stock Subscriptions and Other Receivables | $ 2,200,000 | $ 2,200,000 | $ 2,200,000 | ||||||||||||||||
Series E Preferred Stock [Member] | |||||||||||||||||||
Stock Issued During Period, Value, New Issues | $ 4,980,709 | ||||||||||||||||||
Subsequent Event [Member] | Series E Preferred Stock [Member] | |||||||||||||||||||
Conversion of Stock, Shares Converted (in shares) | 0 | ||||||||||||||||||
Keystone Capital Partners, LLC [Member] | Series D Preferred Stock [Member] | |||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 150,000 | 72,500 | |||||||||||||||||
Stock Issued During Period, Value, New Issues | $ 15,000,000 | ||||||||||||||||||
Stock Purchase Agreement, Shares Remaining (in shares) | 77,500 | 77,500 | 77,500 | ||||||||||||||||
Keystone Capital Partners, LLC [Member] | Series D Preferred Stock [Member] | Maximum [Member] | |||||||||||||||||||
Convertible Preferred Stock, Shares Issued upon Conversion (in shares) | 5,147,000 | ||||||||||||||||||
Keystone Capital Partners, LLC [Member] | Subsequent Event [Member] | Series D Preferred Stock [Member] | |||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 22,077 | ||||||||||||||||||
Stock Issued During Period, Value, New Issues | $ 2,200,000 | ||||||||||||||||||
John K. Scott, Jr. [Member] | Series E Preferred Stock [Member] | |||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 50,000 | ||||||||||||||||||
Stock Issued During Period, Value, New Issues | $ 5,000,000 | ||||||||||||||||||
Preferred Stock, Convertible, Shares Issuable (in shares) | 2,173,913 | ||||||||||||||||||
Private Placement [Member] | |||||||||||||||||||
Stock Issued During Period, Value, New Issues | $ 520,030 | ||||||||||||||||||
Private Placement [Member] | Mastiff Group LLC [Member] | |||||||||||||||||||
Sale of Stock, Commitment Amount | $ 4,975,000 | $ 4,975,000 | $ 4,975,000 | $ 4,975,000 | $ 25,000,000 | ||||||||||||||
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ 0.001 | ||||||||||||||||||
Private Placement [Member] | Mastiff Group LLC [Member] | Subsequent Event [Member] | |||||||||||||||||||
Proceeds from Issuance of Common Stock | $ 25,000 | $ 25,000 | |||||||||||||||||
Platinum-Montaur Life Sciences LLC Litigation [Member] | |||||||||||||||||||
Loss Contingency, Damages Sought, Value | $ 1,900,000 | ||||||||||||||||||
CRG Loan Agreement, Ohio Case [Member] | |||||||||||||||||||
Loss Contingency, Damages Sought, Value | $ 4,300,000 |
Note 3 - Revenue From Contrac_3
Note 3 - Revenue From Contracts With Customers (Details Textual) - USD ($) | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | Dec. 31, 2020 | |
Contract with Customer, Payment Term, Minimum (Day) | 15 days | ||||
Contract with Customer, Payment Term, Maximum (Day) | 90 days | ||||
Contract with Customer, Transaction Price of Royalties Using Expected Value Method | $ 0 | $ 0 | |||
Revenue from Contract with Customer, Including Assessed Tax | 13,000 | $ 9,000 | 36,000 | $ 24,000 | |
Contract with Customer, Asset, Impairment Loss | 0 | 0 | |||
Capitalized Contract Cost, Net, Total | 0 | 0 | |||
Contract with Customer, Asset, after Allowance for Credit Loss, Total | 98,000 | 98,000 | $ 59,000 | ||
Grant [Member] | |||||
Revenue Not from Contract with Customer | $ 73,000 | $ 262,000 | $ 74,000 | $ 403,000 | |
INDIA | |||||
Contract with Customer, Term of Contract (Year) | 8 years | ||||
CHINA | |||||
Contract with Customer, Term of Contract (Year) | 10 years |
Note 3 - Revenue From Contrac_4
Note 3 - Revenue From Contracts With Customers - Disaggregation of Revenue (Details) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Revenue from contract with customer | $ 13,000 | $ 9,000 | $ 36,000 | $ 24,000 |
Royalty [Member] | ||||
Revenue from contract with customer | 0 | 8,920 | 0 | 24,141 |
Diagnostics Segment [Member] | Royalty [Member] | ||||
Revenue from contract with customer | 8,920 | 24,141 | ||
Diagnostics Segment [Member] | Royalty [Member] | Europe [Member] | ||||
Revenue from contract with customer | 0 | 8,920 | 0 | 24,141 |
Diagnostics Segment [Member] | Expanded Tc99m Tilmanocept License Agreement [Member] | Europe [Member] | ||||
Revenue from contract with customer | $ 13,063 | $ 0 | $ 35,549 | $ 0 |
Note 3 - Revenue From Contrac_5
Note 3 - Revenue From Contracts With Customers - Changes in Contract Liabilities (Details) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Total deferred revenue, beginning of period | $ 700,000 | $ 700,000 | $ 700,000 | $ 700,000 |
Revenue deferred related to sublicense | 0 | 160,000 | 0 | 160,000 |
Revenue recognized from satisfaction of performance obligations | 0 | 0 | 0 | 0 |
Total deferred revenue, end of period | $ 700,000 | $ 860,000 | $ 700,000 | $ 860,000 |
Note 4 - Stock-based Compensa_3
Note 4 - Stock-based Compensation (Details Textual) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Share-based Payment Arrangement, Expense | $ 142,000 | $ 35,000 | $ 263,000 | $ 74,000 |
Share-based Payment Arrangement, Expense, Tax Benefit | 0 | $ 0 | $ 0 | $ 0 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ 1.86 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum | 90.22% | |||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | 0.67% | |||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year) | 5 years 11 months 19 days | |||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $ 415,000 | $ 415,000 | ||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) | 1 year 7 months 6 days |
Note 4 - Stock-based Compensa_4
Note 4 - Stock-based Compensation - Summary of Stock Option Activity (Details) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2021USD ($)$ / sharesshares | Dec. 31, 2020USD ($)$ / sharesshares | |
Outstanding at beginning of period (in shares) | shares | 549,970 | |
Outstanding at beginning of period, weighted average exercise price (in dollars per share) | $ / shares | $ 8.81 | |
Outstanding, weighted average remaining contractual life (Year) | 7 years 9 months 18 days | 8 years |
Outstanding, aggregate intrinsic value | $ | $ 143,695 | $ 209,280 |
Granted (in shares) | shares | 232,000 | |
Granted, weighted average exercise price (in dollars per share) | $ / shares | $ 2.54 | |
Exercised (in shares) | shares | (2,000) | |
Exercised, weighted average exercise price (in dollars per share) | $ / shares | $ 1.06 | |
Cancelled/Forfeited (in shares) | shares | (67,600) | |
Cancelled/Forfeited, weighted average exercise price (in dollars per share) | $ / shares | $ 4.01 | |
Outstanding at end of period (in shares) | shares | 712,370 | 549,970 |
Outstanding at end of period, weighted average exercise price (in dollars per share) | $ / shares | $ 7.25 | $ 8.81 |
Exercisable at end of period (in shares) | shares | 186,638 | |
Exercisable at end of period, weighted average exercise price (in dollars per share) | $ / shares | $ 15.64 | |
Exercisable, weighted average remaining contractual life (Year) | 5 years 3 months 18 days | |
Exercisable, aggregate intrinsic value | $ | $ 52,874 |
Note 4 - Stock-based Compensa_5
Note 4 - Stock-based Compensation - Summary of Unvested Restricted Stock (Details) - Restricted Stock [Member] | 6 Months Ended |
Jun. 30, 2021$ / sharesshares | |
Unvested at beginning of period (in shares) | shares | 60,000 |
Unvested at beginning of period, weighted average grant-date fair value (in dollars per share) | $ / shares | $ 2.90 |
Granted (in shares) | shares | 15,000 |
Granted, weighted average grant-date fair value (in dollars per share) | $ / shares | $ 2.17 |
Vested (in shares) | shares | (15,000) |
Vested, weighted average grant-date fair value (in dollars per share) | $ / shares | $ 1.47 |
Unvested at end of period (in shares) | shares | 60,000 |
Unvested at end of period, weighted average grant-date fair value (in dollars per share) | $ / shares | $ 3.08 |
Note 5 - Loss Per Share (Detail
Note 5 - Loss Per Share (Details Textual) - shares | 6 Months Ended | |
Jun. 30, 2021 | Jun. 30, 2020 | |
Stock Options and Warrants [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | 1,684,694 | 1,423,344 |
Restricted Stock [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | 60,000 | 10,000 |
Note 6 - Inventory (Details Tex
Note 6 - Inventory (Details Textual) - USD ($) | 3 Months Ended | 6 Months Ended |
Jun. 30, 2021 | Jun. 30, 2021 | |
Finished Goods [Member] | ||
Inventory, Allocated to Research and Development Expense | $ 1,000 | $ 5,000 |
Note 6 - Inventory - Net Invent
Note 6 - Inventory - Net Inventory (Details) - USD ($) | Jun. 30, 2021 | Dec. 31, 2020 |
Materials | $ 77,750 | $ 77,750 |
Finished goods | 101,080 | 92,048 |
Total inventory | $ 178,830 | $ 169,798 |
Note 8 - Accounts Payable, Ac_2
Note 8 - Accounts Payable, Accrued Liabilities and Other (Details Textual) - Director Fees [Member] - USD ($) | 3 Months Ended | |
Jun. 30, 2021 | Dec. 31, 2020 | |
Related Party Transaction, Percentage of Cash payments | 50.00% | |
Related Party Transaction, Percentage of Stock Payments | 50.00% | |
Accounts Payable [Member] | ||
Due to Related Parties, Current, Total | $ 28,000 | $ 66,000 |
Related Party Transaction, Percentage of Related Party Transaction | 50.00% | |
Accrued Liabilities and Other [Member] | ||
Due to Related Parties, Current, Total | $ 613,000 | $ 755,000 |
Related Party Transaction, Percentage of Related Party Transaction | 50.00% |
Note 9 - Notes Payable (Details
Note 9 - Notes Payable (Details Textual) - USD ($) | Feb. 23, 2021 | May 18, 2020 | Nov. 30, 2020 | Nov. 30, 2019 | Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | Dec. 31, 2020 |
Interest Expense, Debt, Total | $ 1,000 | $ 2,000 | $ 4,000 | $ 5,000 | |||||
Notes Payable, Current, Total | 0 | 0 | $ 745,443 | ||||||
Proceeds from Notes Payable, Total | 0 | 366,000 | |||||||
Gain (Loss) on Extinguishment of Debt, Total | 0 | 0 | 366,000 | 0 | |||||
Notes Payable Issued for Prepayment of Insurance Premiums [Member] | FIF [Member] | |||||||||
Debt Instrument, Face Amount | $ 442,000 | $ 349,000 | |||||||
Debt Instrument, Interest Rate, Stated Percentage | 3.50% | 5.00% | |||||||
Debt Instrument, Term (Month) | 7 months | 8 months | |||||||
Debt Instrument, Periodic Payment, Total | $ 64,000 | $ 44,000 | |||||||
Interest Expense, Debt, Total | 1,000 | $ 2,000 | 4,000 | $ 5,000 | |||||
Notes Payable, Current, Total | $ 0 | $ 0 | $ 379,000 | ||||||
Paycheck Protection Program CARES Act [Member] | |||||||||
Proceeds from Notes Payable, Total | $ 366,000 | ||||||||
Gain (Loss) on Extinguishment of Debt, Total | $ 366,000 |
Note 10 - Leases (Details Textu
Note 10 - Leases (Details Textual) | 1 Months Ended | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2017USD ($) | Jun. 30, 2021USD ($)ft² | Jun. 30, 2020USD ($) | Jun. 30, 2021USD ($)ft² | Jun. 30, 2020USD ($) | |
Operating Lease, Expense | $ 44,000 | $ 50,000 | $ 90,000 | $ 102,000 | |
Operating Lease, Payments | $ 185,000 | $ 181,000 | |||
Office Space at 4995 Bradenton Avenue, Dublin Ohio [Member] | |||||
Area of Real Estate Property (Square Foot) | ft² | 5,000 | 5,000 | |||
Operating Lease, Monthly Base Rent | $ 3,000 | ||||
Office Space at 5600 Blazer Parkway, Dublin, Ohio [Member] | |||||
Area of Real Estate Property (Square Foot) | ft² | 25,000 | 25,000 | |||
Operating Lease, Monthly Base Rent | $ 39,000 | $ 27,000 | |||
Lessee, Operating Lease, Renewal Term (Year) | 5 years | 5 years | |||
Vehicle Lease [Member] | |||||
Operating Lease, Monthly Base Rent | $ 300 | ||||
Office Equipment [Member] | |||||
Operating Lease, Monthly Base Rent | $ 100 |
Note 10 - Leases - Maturity of
Note 10 - Leases - Maturity of Lease Liabilities (Details) | Jun. 30, 2021USD ($) |
2021 (remaining) | $ 159,131 |
2022 | 291,111 |
2023 | 19,699 |
2024 | 1,355 |
Total undiscounted operating lease payments | 471,296 |
Less imputed interest | 36,973 |
Present value of operating lease liabilities | $ 434,323 |
Note 10 - Leases - Balance Shee
Note 10 - Leases - Balance Sheet Classification (Details) - USD ($) | Jun. 30, 2021 | Dec. 31, 2020 |
Current lease liabilities | $ 313,852 | $ 294,951 |
Noncurrent lease liabilities | 120,471 | $ 296,006 |
Present value of operating lease liabilities | 434,323 | |
Other Current Liabilities [Member] | ||
Current lease liabilities | 313,852 | |
Other Noncurrent Liabilities [Member] | ||
Noncurrent lease liabilities | $ 120,471 |
Note 10 - Leases - Other Inform
Note 10 - Leases - Other Information (Details) | Jun. 30, 2021 |
Weighted-average remaining lease term for operating leases (years) (Year) | 1 year 4 months 24 days |
Weighted-average discount rate for operating leases | 11.00% |
Note 11 - Commitments and Con_2
Note 11 - Commitments and Contingencies (Details Textual) - USD ($) | Apr. 21, 2021 | Mar. 16, 2021 | Nov. 27, 2019 | Apr. 09, 2018 | Nov. 02, 2017 | Mar. 03, 2017 | Dec. 31, 2019 | Nov. 30, 2018 | Aug. 31, 2018 | Nov. 30, 2017 | Jun. 30, 2016 | Jun. 30, 2021 | Dec. 31, 2020 |
Stock Issued During Period, Shares, New Issues (in shares) | 2,100,000 | ||||||||||||
Stockholders' Equity Attributable to Parent, Ending Balance | $ 5,704,870 | $ 1,315,604 | |||||||||||
Market Capitalization, Fair Value | $ 55,200,000 | ||||||||||||
Common Stock [Member] | |||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 0 | ||||||||||||
Former Chief Executive Officer and President [Member] | |||||||||||||
Common Stock Shares Provided by Agreement (in shares) | 1,175,000 | ||||||||||||
Common Stock Shares Provided by Agreement, Escrow Period (Month) | 18 months | ||||||||||||
Former Chief Executive Officer and President [Member] | Common Stock [Member] | |||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 925,000 | ||||||||||||
Stock Issued During Period, Shares, New Issues Placed in Escrow (in shares) | 250,000 | ||||||||||||
Former Chief Executive Officer and President [Member] | MT [Member] | Common Stock [Member] | Dr. Michael Goldberg [Member] | |||||||||||||
Ownership Percentage | 5.00% | ||||||||||||
CRG [Member] | |||||||||||||
Draws on Letter of Credit | $ 7,100,000 | ||||||||||||
CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member] | |||||||||||||
Loss Contingency, Damages Awarded, Value, Additional Amount | $ 7,000,000 | ||||||||||||
Loss Contingency, Damages Awarded, Value, Amount not Taken into Consideration | $ 4,100,000 | ||||||||||||
Ohio Court of Common Pleas [Member] | |||||||||||||
Litigation Settlement, Amount Awarded from Other Party | $ 4,300,000 | ||||||||||||
Litigation Settlement, Reversal of Amount Awarded from Other Party | $ 4,300,000 | ||||||||||||
Platinum-Montaur Life Sciences LLC Litigation [Member] | |||||||||||||
Loss Contingency, Damages Sought, Value | $ 1,900,000 | ||||||||||||
Platinum-Montaur Life Sciences LLC Litigation [Member] | Pending Litigation [Member] | |||||||||||||
Loss Contingency, Damages Sought, Value | $ 1,900,000 | ||||||||||||
New York Litigation Involving Former CEO and President [Member] | Judicial Ruling [Member] | |||||||||||||
Litigation Settlement, Amount Can Be Awarded to Other Party for Indemnification for Attorneys’ Fees | $ 14,955 | ||||||||||||
Litigation Settlement, Amount Can Be Advanced to Other Party for Attorneys’ Fees Subject to Repayment | $ 1,237.50 | ||||||||||||
CRG [Member] | Term Loan Agreement [Member] | CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member] | |||||||||||||
Repayments of Debt | 59,000,000 | ||||||||||||
CRG [Member] | Term Loan Agreement [Member] | Maximum [Member] | |||||||||||||
Debt Instrument, Agreed-upon Final Payoff Amount | $ 66,000,000 |
Note 12 - Equity (Details Textu
Note 12 - Equity (Details Textual) - USD ($) | Aug. 12, 2021 | Jul. 08, 2021 | Mar. 02, 2021 | Aug. 31, 2020 | Aug. 12, 2021 | Feb. 29, 2020 | Jan. 31, 2020 | Dec. 31, 2019 | Jun. 30, 2021 | Mar. 31, 2021 | Jun. 30, 2020 | Mar. 31, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | Aug. 30, 2020 |
Stock Issued During Period, Shares, New Issues (in shares) | 2,100,000 | |||||||||||||||||
Proceeds from Issuance of Common Stock | $ 812,000 | $ 1,900,000 | $ 2,133 | $ 3,025,040 | $ 1,100,000 | |||||||||||||
Common Stock, Share Subscribed but Unissued, Subscriptions Receivable | $ 0 | 0 | $ 0 | $ 4,975,000 | ||||||||||||||
Proceeds from Issuance of Preferred Stock and Preference Stock | $ 10,475,000 | $ 700,000 | ||||||||||||||||
Stock Issued During Period, Value, New Issues | $ 1,800,000 | $ 700,000 | ||||||||||||||||
Stock Issued During Period, Shares, Employee Benefit Plan (in shares) | 30,018 | 32,651 | ||||||||||||||||
Stock Issued During Period, Value, Employee Benefit Plan | $ 76,846 | $ 39,834 | $ 77,000 | $ 40,000 | ||||||||||||||
Issuance of Stock to Defined Contribution Plan for Employer Matching Contribution | $ 76,846 | $ 39,834 | ||||||||||||||||
Common Stock [Member] | ||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 0 | |||||||||||||||||
Stock Issued During Period, Value, New Issues | $ 0 | |||||||||||||||||
Stock Issued During Period, Shares, Employee Benefit Plan (in shares) | 30,018 | 32,651 | ||||||||||||||||
Stock Issued During Period, Value, Employee Benefit Plan | $ 30 | $ 33 | ||||||||||||||||
Stock Issued During Period, Shares, Issued for Employee Bonuses (in shares) | 40,844 | 53,315 | ||||||||||||||||
Conversion from Series D Preferred Stock To Common Stock [Member] | ||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 72,500 | |||||||||||||||||
Stock Subscriptions Receivable | 7,250,000 | $ 7,250,000 | $ 7,250,000 | |||||||||||||||
Series D Preferred Stock [Member] | ||||||||||||||||||
Stock Issued During Period, Value, New Issues | 250,001 | |||||||||||||||||
Series E Preferred Stock [Member] | ||||||||||||||||||
Stock Issued During Period, Value, New Issues | $ 4,980,709 | |||||||||||||||||
Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ 2.30 | |||||||||||||||||
Preferred Stock, Redemption Price Per Share (in dollars per share) | $ 110 | |||||||||||||||||
Subsequent Event [Member] | Conversion from Series D Preferred Stock To Common Stock [Member] | ||||||||||||||||||
Conversion of Stock, Shares Converted (in shares) | 72,500 | |||||||||||||||||
Conversion of Stock, Shares Issued (in shares) | 3,778,789 | |||||||||||||||||
Subsequent Event [Member] | Series E Preferred Stock [Member] | ||||||||||||||||||
Conversion of Stock, Shares Converted (in shares) | 0 | |||||||||||||||||
Keystone Capital Partners, LLC [Member] | Series D Preferred Stock [Member] | ||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 150,000 | 72,500 | ||||||||||||||||
Stock Issued During Period, Value, Other | $ 15,000,000 | |||||||||||||||||
Proceeds from Issuance of Preferred Stock and Preference Stock | 2,925,000 | 2,925,000 | ||||||||||||||||
Stock Issued During Period, Value, New Issues | $ 15,000,000 | |||||||||||||||||
Keystone Capital Partners, LLC [Member] | Series D Preferred Stock [Member] | Maximum [Member] | ||||||||||||||||||
Convertible Preferred Stock, Shares Issued upon Conversion (in shares) | 5,147,000 | |||||||||||||||||
Keystone Capital Partners, LLC [Member] | Subsequent Event [Member] | Series D Preferred Stock [Member] | ||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 22,077 | |||||||||||||||||
Proceeds from Issuance of Preferred Stock and Preference Stock | $ 2,200,000 | |||||||||||||||||
Stock Issued During Period, Value, New Issues | $ 2,200,000 | |||||||||||||||||
John K. Scott, Jr. [Member] | Series E Preferred Stock [Member] | ||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 50,000 | |||||||||||||||||
Stock Issued During Period, Value, New Issues | $ 5,000,000 | |||||||||||||||||
Percentage of Securities Allowed to be Purchased in Third-Party Offering, Maximum | 33.33% | |||||||||||||||||
Private Placement [Member] | ||||||||||||||||||
Stock Issued During Period, Value, New Issues | $ 520,030 | |||||||||||||||||
Private Placement [Member] | Common Stock [Member] | ||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 1,911,800 | 902,162 | ||||||||||||||||
Stock Issued During Period, Value, New Issues | $ 1,912 | $ 902 | ||||||||||||||||
Private Placement [Member] | Mastiff Group LLC [Member] | ||||||||||||||||||
Sale of Stock, Commitment Amount | $ 4,975,000 | $ 4,975,000 | $ 4,975,000 | $ 4,975,000 | $ 25,000,000 | |||||||||||||
Private Placement [Member] | Mastiff Group LLC [Member] | Subsequent Event [Member] | ||||||||||||||||||
Proceeds from Issuance of Common Stock | $ 25,000 | $ 25,000 | ||||||||||||||||
Investor [Member] | ||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 4,000,000 | 4,020,588 | ||||||||||||||||
Proceeds from Issuance of Common Stock | $ 3,400,000 | $ 3,400,000 | ||||||||||||||||
Employees [Member] | Common Stock [Member] | ||||||||||||||||||
Stock Issued During Period, Shares, Issued for Employee Bonuses (in shares) | 94,159 | |||||||||||||||||
Issuance of Stock to Defined Contribution Plan for Employer Matching Contribution | $ 172,000 | |||||||||||||||||
Prepaid Expenses and Other Current Assets [Member] | ||||||||||||||||||
Common Stock, Share Subscribed but Unissued, Subscriptions Receivable | $ 812,000 | $ 812,000 |
Note 13 - Stock Warrants (Detai
Note 13 - Stock Warrants (Details Textual) | Jun. 30, 2021$ / sharesshares |
Class of Warrant or Right, Outstanding (in shares) | shares | 972,324 |
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 17.97 |
Minimum [Member] | |
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.20 |
Warrants and Rights Outstanding, Term (Month) | 8 months |
Maximum [Member] | |
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 49.80 |
Warrants and Rights Outstanding, Term (Month) | 14 years 1 month 6 days |
Note 14 - Income Taxes (Details
Note 14 - Income Taxes (Details Textual) - USD ($) $ in Thousands | 6 Months Ended | |
Jun. 30, 2021 | Dec. 31, 2020 | |
Unrecognized Tax Benefits, Ending Balance | $ 0 | $ 0 |
Domestic Tax Authority [Member] | ||
Operating Loss Carryforwards, Total | $ 153,300 | |
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | ||
Open Tax Year | 2017 2018 2019 2020 | |
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member] | ||
Tax Credit Carryforward, Amount | $ 8,900 | |
State and Local Jurisdiction [Member] | ||
Open Tax Year | 2017 2018 2019 2020 | |
Operating Loss Carryforwards, Total | $ 20,100 |
Note 15 - Segments (Details Tex
Note 15 - Segments (Details Textual) | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2021USD ($) | Jun. 30, 2020USD ($) | Jun. 30, 2021USD ($) | Jun. 30, 2020USD ($) | ||
Revenues, Total | $ 261,046 | $ 271,101 | $ 384,783 | $ 427,373 | |
Number of Primary Types of Products Sold | 2 | 2 | |||
Depreciation, Depletion and Amortization, Nonproduction, Total | [1] | $ 19,858 | $ 19,256 | $ 37,606 | $ 36,099 |
Intersegment Eliminations [Member] | |||||
Revenues, Total | $ 0 | ||||
[1] | Depreciation and amortization are reflected in selling, general and administrative expenses ($19,858 and $19,256 for the three-month periods ended June 30, 2021 and 2020, and $37,606 and $36,099 for the six-month periods ended June 30, 2021 and 2020, respectively). |
Note 15 - Segments - Segment In
Note 15 - Segments - Segment Information (Details) - USD ($) | 3 Months Ended | 6 Months Ended | |||||||||
Jun. 30, 2021 | Mar. 31, 2021 | Jun. 30, 2020 | Mar. 31, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | Dec. 31, 2020 | |||||
Revenue from contract with customer | $ 13,000 | $ 9,000 | $ 36,000 | $ 24,000 | |||||||
Grant and other revenue | 247,983 | 262,181 | 349,234 | 403,232 | |||||||
Revenues, Total | 261,046 | 271,101 | 384,783 | 427,373 | |||||||
Research and development expenses | 1,498,056 | 1,281,779 | 2,720,810 | 2,281,048 | |||||||
Selling, general and administrative expenses, excluding depreciation and amortization | [1] | 1,412,752 | 1,310,335 | 3,625,749 | 3,121,246 | ||||||
Depreciation, Depletion and Amortization, Nonproduction, Total | [2] | 19,858 | 19,256 | 37,606 | 36,099 | ||||||
Loss from operations | [3] | (2,669,620) | (2,340,626) | (5,999,382) | (5,011,986) | ||||||
Other expense (4) | [4] | (4,420) | |||||||||
Net loss | (2,674,040) | $ (2,966,892) | (2,325,619) | $ (2,673,608) | (5,640,932) | (4,999,227) | |||||
Total assets, net of depreciation and amortization | 11,281,310 | 11,281,310 | $ 7,758,018 | ||||||||
Capital expenditures | 2,707 | 1,947 | 2,707 | 8,406 | |||||||
Cost of revenue | 0 | 357 | 0 | 966 | |||||||
Other income (4) | (4,420) | 15,007 | [4] | 358,450 | [4] | 12,759 | [4] | ||||
UNITED STATES | |||||||||||
Total assets, net of depreciation and amortization | 11,080,979 | 6,606,683 | 11,080,979 | 6,606,683 | |||||||
Non-US [Member] | |||||||||||
Total assets, net of depreciation and amortization | 200,331 | 200,331 | |||||||||
License [Member] | |||||||||||
Revenue from contract with customer | 13,063 | 0 | 35,549 | 0 | |||||||
Royalty [Member] | |||||||||||
Revenue from contract with customer | 0 | 8,920 | 0 | 24,141 | |||||||
Diagnostics Segment [Member] | |||||||||||
Grant and other revenue | 247,983 | 215,458 | 349,234 | 274,374 | |||||||
Revenues, Total | 261,046 | 224,378 | 384,783 | 298,515 | |||||||
Research and development expenses | 1,358,123 | 1,193,151 | 2,452,513 | 2,150,777 | |||||||
Selling, general and administrative expenses, excluding depreciation and amortization | [1] | 0 | 0 | 0 | 0 | ||||||
Depreciation, Depletion and Amortization, Nonproduction, Total | [2] | 6,041 | 0 | 12,081 | 0 | ||||||
Loss from operations | [3] | (1,103,118) | (969,130) | (2,079,811) | (1,853,228) | ||||||
Other expense (4) | [4] | 0 | |||||||||
Net loss | (1,103,118) | (969,130) | (2,079,811) | (1,853,228) | |||||||
Capital expenditures | 0 | 0 | 0 | 0 | |||||||
Cost of revenue | 357 | 966 | |||||||||
Other income (4) | [4] | 0 | 0 | 0 | |||||||
Diagnostics Segment [Member] | UNITED STATES | |||||||||||
Total assets, net of depreciation and amortization | 269,464 | 107,185 | 269,464 | 107,185 | |||||||
Diagnostics Segment [Member] | Non-US [Member] | |||||||||||
Total assets, net of depreciation and amortization | 199,741 | 199,741 | |||||||||
Diagnostics Segment [Member] | License [Member] | |||||||||||
Revenue from contract with customer | 13,063 | 35,549 | |||||||||
Diagnostics Segment [Member] | Royalty [Member] | |||||||||||
Revenue from contract with customer | 8,920 | 24,141 | |||||||||
Therapeutics Segment [Member] | |||||||||||
Grant and other revenue | 0 | 46,723 | 0 | 128,858 | |||||||
Revenues, Total | 0 | 46,723 | 0 | 128,858 | |||||||
Research and development expenses | 139,933 | 88,628 | 268,297 | 130,271 | |||||||
Selling, general and administrative expenses, excluding depreciation and amortization | [1] | 873 | 972 | 2,879 | (550) | ||||||
Depreciation, Depletion and Amortization, Nonproduction, Total | [2] | 0 | 0 | 0 | 0 | ||||||
Loss from operations | [3] | (140,806) | (42,877) | (271,176) | (863) | ||||||
Other expense (4) | [4] | 0 | |||||||||
Net loss | (140,806) | (42,877) | (271,176) | (863) | |||||||
Capital expenditures | 0 | 0 | 0 | 0 | |||||||
Cost of revenue | 0 | 0 | |||||||||
Other income (4) | [4] | 0 | 0 | 0 | |||||||
Therapeutics Segment [Member] | UNITED STATES | |||||||||||
Total assets, net of depreciation and amortization | 0 | 36,483 | 0 | 36,483 | |||||||
Therapeutics Segment [Member] | Non-US [Member] | |||||||||||
Total assets, net of depreciation and amortization | 0 | 0 | |||||||||
Therapeutics Segment [Member] | License [Member] | |||||||||||
Revenue from contract with customer | 0 | 0 | |||||||||
Therapeutics Segment [Member] | Royalty [Member] | |||||||||||
Revenue from contract with customer | 0 | 0 | |||||||||
Corporate Segment [Member] | |||||||||||
Grant and other revenue | 0 | 0 | 0 | 0 | |||||||
Revenues, Total | 0 | 0 | 0 | 0 | |||||||
Research and development expenses | 0 | 0 | 0 | 0 | |||||||
Selling, general and administrative expenses, excluding depreciation and amortization | [1] | 1,411,879 | 1,309,363 | 3,622,870 | 3,121,796 | ||||||
Depreciation, Depletion and Amortization, Nonproduction, Total | [2] | 13,817 | 19,256 | 25,525 | 36,099 | ||||||
Loss from operations | [3] | (1,425,696) | (1,328,619) | (3,648,395) | (3,157,895) | ||||||
Other expense (4) | [4] | (4,420) | |||||||||
Net loss | (1,430,116) | (1,313,612) | (3,289,945) | (3,145,136) | |||||||
Capital expenditures | 2,707 | 1,947 | 2,707 | 8,406 | |||||||
Cost of revenue | 0 | 0 | |||||||||
Other income (4) | [4] | 15,007 | 358,450 | 12,759 | |||||||
Corporate Segment [Member] | UNITED STATES | |||||||||||
Total assets, net of depreciation and amortization | 10,811,515 | 6,463,015 | 10,811,515 | 6,463,015 | |||||||
Corporate Segment [Member] | Non-US [Member] | |||||||||||
Total assets, net of depreciation and amortization | 590 | 590 | |||||||||
Corporate Segment [Member] | License [Member] | |||||||||||
Revenue from contract with customer | $ 0 | $ 0 | |||||||||
Corporate Segment [Member] | Royalty [Member] | |||||||||||
Revenue from contract with customer | $ 0 | $ 0 | |||||||||
[1] | General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments, other than those expenses directly incurred by Navidea Europe, Navidea UK and MT. | ||||||||||
[2] | Depreciation and amortization are reflected in selling, general and administrative expenses ($19,858 and $19,256 for the three-month periods ended June 30, 2021 and 2020, and $37,606 and $36,099 for the six-month periods ended June 30, 2021 and 2020, respectively). | ||||||||||
[3] | Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments, other than those expenses directly incurred by Navidea Europe, Navidea UK and MT. | ||||||||||
[4] | Amounts consist primarily of interest income and interest expense, which are not currently allocated to our individual reportable segments. |
Note 16 - Supplemental Disclo_2
Note 16 - Supplemental Disclosure for Statements of Cash Flows (Details Textual) - USD ($) | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||
Feb. 29, 2020 | Mar. 31, 2021 | Jun. 30, 2020 | Mar. 31, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | Dec. 31, 2020 | |
Interest Paid, Excluding Capitalized Interest, Operating Activities | $ 4,000 | $ 5,000 | |||||
Proceeds from Issuance of Preferred Stock and Preference Stock | $ 10,475,000 | $ 700,000 | |||||
Stock Issued During Period, Shares, Employee Benefit Plan (in shares) | 30,018 | 32,651 | |||||
Stock Issued During Period, Value, Employee Benefit Plan | $ 76,846 | $ 39,834 | $ 77,000 | $ 40,000 | |||
Issuance of Stock to Defined Contribution Plan for Employer Matching Contribution | 76,846 | $ 39,834 | |||||
Conversion from Series C Preferred Stock To Common Stock [Member] | |||||||
Conversion of Stock, Shares Converted (in shares) | 70,000 | ||||||
Conversion of Stock, Shares Issued (in shares) | 410,765 | ||||||
Series OO Warrants [Member] | |||||||
Class of Warrant or Right, Exercised During Period (in shares) | 411,000 | ||||||
Issued Stock Upon Exercise of Warrants, Shares (in shares) | 300,595 | ||||||
Common Stock [Member] | |||||||
Stock Issued During Period, Shares, Employee Benefit Plan (in shares) | 30,018 | 32,651 | |||||
Stock Issued During Period, Value, Employee Benefit Plan | $ 30 | $ 33 | |||||
Stock Issued During Period, Shares, Issued for Employee Bonuses (in shares) | 40,844 | 53,315 | |||||
Employees [Member] | Common Stock [Member] | |||||||
Stock Issued During Period, Shares, Issued for Employee Bonuses (in shares) | 94,159 | ||||||
Issuance of Stock to Defined Contribution Plan for Employer Matching Contribution | $ 172,000 | ||||||
Office Lease [Member] | |||||||
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability | $ 100,432 | ||||||
Series D Preferred Stock [Member] | Keystone Capital Partners, LLC [Member] | |||||||
Proceeds from Issuance of Preferred Stock and Preference Stock | $ 2,925,000 | $ 2,925,000 | |||||
Series C Preferred Stock [Member] | |||||||
Preferred Stock, Deemed Dividend | $ 78,000 | ||||||
Conversion of Stock, Shares Converted (in shares) | 70,000 |
Note 17 - Subsequent Events (De
Note 17 - Subsequent Events (Details Textual) - USD ($) | Jul. 08, 2021 | Aug. 31, 2020 | Dec. 31, 2019 | Jun. 30, 2021 | Mar. 31, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Dec. 31, 2020 |
Stock Issued During Period, Shares, New Issues (in shares) | 2,100,000 | |||||||||
Stock Issued During Period, Value, New Issues | $ 1,800,000 | $ 700,000 | ||||||||
Proceeds from Issuance of Preferred Stock and Preference Stock | $ 10,475,000 | $ 700,000 | ||||||||
Series D Preferred Stock [Member] | ||||||||||
Stock Issued During Period, Value, New Issues | $ 250,001 | |||||||||
Preferred Stock, Shares Subscribed but Unissued, Subscriptions Receivable | 0 | 0 | $ 0 | $ 10,300,000 | ||||||
Series D Preferred Stock [Member] | Stock Subscriptions and Other Receivables [Member] | ||||||||||
Preferred Stock, Shares Subscribed but Unissued, Subscriptions Receivable | $ 2,200,000 | $ 2,200,000 | $ 2,200,000 | |||||||
Keystone Capital Partners, LLC [Member] | Series D Preferred Stock [Member] | ||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 150,000 | 72,500 | ||||||||
Stock Issued During Period, Value, New Issues | $ 15,000,000 | |||||||||
Stock Purchase Agreement, Shares Remaining (in shares) | 77,500 | 77,500 | 77,500 | |||||||
Proceeds from Issuance of Preferred Stock and Preference Stock | $ 2,925,000 | $ 2,925,000 | ||||||||
Subsequent Event [Member] | Keystone Capital Partners, LLC [Member] | Series D Preferred Stock [Member] | ||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 22,077 | |||||||||
Stock Issued During Period, Value, New Issues | $ 2,200,000 | |||||||||
Proceeds from Issuance of Preferred Stock and Preference Stock | $ 2,200,000 |
Uncategorized Items - navb20210
Label | Element | Value |
Issued stock upon stock option exercise | us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised | $ 2,120 |
Issued restricted stock | us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross | 13 |
us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest | us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest | 5,008,882 |
Stock compensation expense | us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue | 121,298 |
Stock compensation expense | us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue | 142,180 |
Retained Earnings [Member] | ||
Issued stock | us-gaap_StockIssuedDuringPeriodValueNewIssues | 0 |
Net loss | us-gaap_ProfitLoss | (2,966,890) |
Net loss | us-gaap_ProfitLoss | $ (2,764,039) |
Common Stock [Member] | ||
Issued stock upon conversion of Preferred Stock (in shares) | us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities | 1,437,531 |
Issued stock upon stock option exercise | us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised | $ 2 |
Issued stock upon conversion of Series D Preferred Stock | us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities | 1,437 |
Issued restricted stock | us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross | $ 13 |
Issued stock upon stock option exercise (in shares) | us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised | 2,000 |
Issued restricted stock (in shares) | us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited | 12,500 |
Preferred Stock [Member] | ||
Issued stock | us-gaap_StockIssuedDuringPeriodValueNewIssues | $ 23 |
Issued stock upon conversion of Preferred Stock (in shares) | us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities | (23,000) |
Issued stock (in shares) | us-gaap_StockIssuedDuringPeriodSharesNewIssues | 23,000 |
Issued stock upon conversion of Series D Preferred Stock | us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities | $ (23) |
Noncontrolling Interest [Member] | ||
Issued stock | us-gaap_StockIssuedDuringPeriodValueNewIssues | 0 |
Net loss | us-gaap_ProfitLoss | (2) |
Net loss | us-gaap_ProfitLoss | (1) |
Additional Paid-in Capital [Member] | ||
Issued stock | us-gaap_StockIssuedDuringPeriodValueNewIssues | 0 |
Stock subscribed | navb_StockSubscribedDuringPeriodValue | 4,974,005 |
Issued stock upon stock option exercise | us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised | 2,118 |
Issued stock upon conversion of Series D Preferred Stock | us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities | (1,414) |
Stock compensation expense | us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue | 121,298 |
Stock compensation expense | us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue | 142,180 |
Issued stock to 401(k) Plan | us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan | 76,816 |
Stock issuance cost | us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts | 50,671 |
Common Stock Subscription [Member] | ||
Issued stock | us-gaap_StockIssuedDuringPeriodValueNewIssues | 0 |
Stock subscribed | navb_StockSubscribedDuringPeriodValue | $ 995 |
Issued stock (in shares) | us-gaap_StockIssuedDuringPeriodSharesNewIssues | 0 |
Stock subscribed (in shares) | navb_StockSubscribedDuringPeriodShares | 995,000 |
Preferred Stock Subscriptions Receivable [Member] | ||
Issued stock | us-gaap_StockIssuedDuringPeriodValueNewIssues | $ 1,800,000 |
Common Stock Subscriptions Receivable [Member] | ||
Issued stock | us-gaap_StockIssuedDuringPeriodValueNewIssues | 0 |
Stock subscribed | navb_StockSubscribedDuringPeriodValue | (4,975,000) |
Preferred Stock Subscription [Member] | ||
Issued stock | us-gaap_StockIssuedDuringPeriodValueNewIssues | $ (23) |
Issued stock (in shares) | us-gaap_StockIssuedDuringPeriodSharesNewIssues | (23,000) |
Series E Preferred Stock [Member] | Preferred Stock [Member] | ||
Issued stock | us-gaap_StockIssuedDuringPeriodValueNewIssues | $ 50 |
Issued stock (in shares) | us-gaap_StockIssuedDuringPeriodSharesNewIssues | 50,000 |
Series E Preferred Stock [Member] | Additional Paid-in Capital [Member] | ||
Issued stock | us-gaap_StockIssuedDuringPeriodValueNewIssues | $ 4,980,659 |
Series D Preferred Stock [Member] | ||
Stock subscribed | navb_StockSubscribedDuringPeriodValue | 500,000 |
Stock subscribed | navb_StockSubscribedDuringPeriodValue | $ (2,207,699) |
Series D Preferred Stock [Member] | Common Stock [Member] | ||
Issued stock upon conversion of Preferred Stock (in shares) | us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities | 1,513,978 |
Issued stock upon conversion of Series D Preferred Stock | us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities | $ 1,514 |
Series D Preferred Stock [Member] | Preferred Stock [Member] | ||
Issued stock | us-gaap_StockIssuedDuringPeriodValueNewIssues | $ 32 |
Issued stock upon conversion of Preferred Stock (in shares) | us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities | (31,750) |
Issued stock (in shares) | us-gaap_StockIssuedDuringPeriodSharesNewIssues | 31,750 |
Issued stock upon conversion of Series D Preferred Stock | us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities | $ (32) |
Series D Preferred Stock [Member] | Additional Paid-in Capital [Member] | ||
Stock subscribed | navb_StockSubscribedDuringPeriodValue | 5,542,245 |
Issued stock upon conversion of Series D Preferred Stock | us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities | (1,482) |
Series D Preferred Stock [Member] | Preferred Stock Subscriptions Receivable [Member] | ||
Issued stock | us-gaap_StockIssuedDuringPeriodValueNewIssues | 250,000 |
Stock subscribed | navb_StockSubscribedDuringPeriodValue | 500,000 |
Stock subscribed | navb_StockSubscribedDuringPeriodValue | (7,750,000) |
Series D Preferred Stock [Member] | Preferred Stock Subscription [Member] | ||
Issued stock | us-gaap_StockIssuedDuringPeriodValueNewIssues | (31) |
Stock subscribed | navb_StockSubscribedDuringPeriodValue | $ 56 |
Issued stock (in shares) | us-gaap_StockIssuedDuringPeriodSharesNewIssues | (31,750) |
Stock subscribed (in shares) | navb_StockSubscribedDuringPeriodShares | 55,423 |